Status:

RECRUITING

A Phase 1/1B Study of ST-01156, a Small Molecule RBM39 Degrader, in Patients With Advanced Solid Malignancies

Lead Sponsor:

SEED Therapeutics, Inc.

Conditions:

Advanced Solid Tumors

Ewing Sarcoma

Eligibility:

All Genders

16+ years

Phase:

PHASE1

Brief Summary

A Phase 1/1B Study of ST-01156 in Patients with Advanced Solid Malignancies

Detailed Description

This Phase 1/1b study is evaluating the safety, tolerability, and preliminary anticancer activity of ST-01156 in participants with advanced solid malignancies. The study will be conducted in 2 parts. ...

Eligibility Criteria

Inclusion

  • Age ≥ 18 years on the day of signing the consent form, except for adolescents with Ewing Sarcoma or other malignancies for which there is a biological rationale to support participation, in which case the participant is ≥ 16 years old.
  • Has a metastatic or locally advanced and unresectable solid tumor.
  • Has at least 1 measurable lesion or evaluable disease per RECIST v1.1.
  • Has an ECOG performance status ≤ 2 at screening.
  • Has adequate organ function as defined in the protocol.

Exclusion

  • Has received prior radiotherapy within 2 weeks of treatment.
  • Has known active CNS metastases and/or carcinomatous meningitis. Participants with previously treated brain metastases may participate, provided they are radiologically stable
  • Has received treatment with any local or systemic anticancer therapy or investigational anticancer agent within 14 days or 5 half-lives, whichever is shorter.
  • Had major surgery within 28 days before study therapy administration
  • Has toxicities from previous anticancer therapies that have not resolved to baseline levels, with the exception of alopecia and peripheral neuropathy.
  • Has previously received a RBM39 inhibitor/degrader.

Key Trial Info

Start Date :

December 1 2025

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

December 31 2029

Estimated Enrollment :

171 Patients enrolled

Trial Details

Trial ID

NCT07197554

Start Date

December 1 2025

End Date

December 31 2029

Last Update

December 18 2025

Active Locations (6)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 2 (6 locations)

1

The City of Hope National Medical Center

Duarte, California, United States, 91010

2

Hoag Memorial Hospital

Newport Beach, California, United States, 92263

3

Mass General Brigham Cancer Institute

Boston, Massachusetts, United States, 02114

4

Dana Farber Cancer Institute

Boston, Massachusetts, United States, 02215